|
Per patient and cycle pharmacological costs
| |
€4,046
|
€4,904
|
-€858
|
-17.50%
|
|
Per patient annual (8 cycles) pharmacological costs
| |
€32,365
|
€39,232
|
-€6,867
|
-17.50%
|
|
Per patient annual costs associated with AE management
| |
€662
|
€974
|
-€312
|
-32.03%
|
|
Per patient overall annual costs
| |
€33,027
|
€40,206
|
-€7,179
|
-17.85%
|
|
Year 2013
| | | | | |
|
Advanced RCC at diagnosis
|
854
| | | | |
|
Progressions to advanced RCC
|
934
| | | | |
|
Advanced RCC (favorable or intermediate risk)
|
1,591
| | | | |
|
Pharmacological costs
| |
€29,350,968
|
€35,578,198
|
-€6,227,230
|
-17.50%
|
|
Overall costs
| |
€30,404,210
|
€37,127,832
|
-€6,723,622
|
-18.11%
|
|
Year 2014
| | | | | |
|
Advanced RCC at diagnosis
|
866
| | | | |
|
Progressions to advanced RCC
|
948
| | | | |
|
Advanced RCC (favorable or intermediate risk)
|
1,615
| | | | |
|
Pharmacological costs
| |
€28,925,945
|
€35,063,000
|
-€6,137,056
|
-17.50%
|
|
Overall costs
| |
€29,963,935
|
€36,590,195
|
-€6,626,260
|
-18.11%
|
|
Year 2015
| | | | | |
|
Advanced RCC at diagnosis
|
878
| | | | |
|
Progressions to advanced RCC
|
962
| | | | |
|
Advanced RCC (favorable or intermediate risk)
|
1,638
| | | | |
|
Pharmacological costs
| |
€28,483,391
|
€34,526,553
|
-€6,043,162
|
-17.50%
|
|
Overall costs
| |
€29,505,501
|
€36,030,382
|
-€6,524,881
|
-18.11%
|
